Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trialReinier C A van Linschoten, Aura A. J. van Esch, Fenna M. Jansen et al.|The Lancet. Gastroenterology & hepatology|2023Cited by 21
Predicting mucosal inflammation in IBD patients using patient-reported symptom scores and a faecal calprotectin home test: protocol for a multicentre prospective validation studyLaura Janssen, M Pierik, Reinier C A van Linschoten et al.|BMJ Open|2024Cited by 5
Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn’s Disease Patients in Stable Remission: The Randomized Controlled LADI TrialFenna M. Jansen, Aura A. J. van Esch, Reinier C A van Linschoten et al.|Journal of Crohn s and Colitis|2023Cited by 4
Prevalence, incidence, and mortality of inflammatory bowel disease in the Netherlands: development and external validation of machine learning modelsReinier C A van Linschoten, Desirée van Noord, Nikki van Leeuwen et al.|Journal of Crohn s and Colitis|2025Cited by 4
A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn’s Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI TrialReinier C A van Linschoten, Fenna M. Jansen, R Pauwels et al.|Digestive Diseases and Sciences|2024Cited by 2